The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted ...

Columnist Kristin Neva sometimes get overwhelmed by her increasing caregiver responsibilities, but it helps her to know she's not alone.

Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS Pharmaceutics to combine efforts to advance both companies’ drug portfolios. The ...